Challenges related to developing serum-based biomarkers for early ovarian cancer detection
- PMID: 21372029
- PMCID: PMC3077065
- DOI: 10.1158/1940-6207.CAPR-11-0053
Challenges related to developing serum-based biomarkers for early ovarian cancer detection
Abstract
In this issue of the journal, Cramer and colleagues and Zhu and colleagues report carefully designed phase 3 assessments of candidate ovarian cancer screening biomarkers. The main conclusion is that CA-125 remains the "best of a bad lot"; the new candidates have fallen short of expectations. We review factors impeding the development of an effective ovarian cancer screening strategy, highlight the requirements related to validating proposed screening biomarkers, and emphasize the risks from premature clinical applications of unvalidated tests, all underscoring the need for new research strategies.
Comment on
-
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195. Cancer Prev Res (Phila). 2011. PMID: 21372036 Free PMC article.
-
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193. Cancer Prev Res (Phila). 2011. PMID: 21372037 Free PMC article.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277–300. - PubMed
-
- Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol. 2010 Jun;7(6):335–9. - PubMed
-
- Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC, Jr., et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul;80(1):14–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
